---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-292057"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2025-11-24T23:59:59+00:00"
generated_at: "2026-05-16T17:20:25.638333+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IN8bio presents GBM trial data: mPFS 13.0 mo vs 6.6 SOC; mOS not reached at 16.4+ mo

## Summary
- Phase 1 INB-200 and Phase 2 INB-400 data presented at SNO 2025 for newly diagnosed glioblastoma.
- 14 patients received repeated DeltEx DRI gamma-delta T cells; mPFS 13.0 months vs 6.6 for SOC (n=10).
- Median OS not yet reached for DRI patients at 16.4+ months as of Oct 31, 2025; SOC mOS 11.0 months.
- 17 patients treated across both trials; 10 additional SOC-only patients monitored for comparison.

## SEC filing metadata
- accession: 0001193125-25-292057
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2025-11-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312525292057/0001193125-25-292057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312525292057/d11812d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-292057
- JSON: https://secwatch.observer/filing/0001193125-25-292057.json
- Plain text: https://secwatch.observer/filing/0001193125-25-292057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.